Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: FNG017
MIFTS: 53

Fungal Infectious Disease

Categories: Infectious diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Fungal Infectious Disease

About this section

MalaCards integrated aliases for Fungal Infectious Disease:

Name: Fungal Infectious Disease 12 15
Mycoses 12 43 15 32
Mycosis 12

Classifications:

MalaCards categories:
Global: Infectious diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:1564
ICD9CM 34 110-118.99
MeSH 43 D009181
NCIt 49 C3245
SNOMED-CT 67 3218000
UMLS 71 C0026946
Sources

Summaries for Fungal Infectious Disease

About this section
Disease Ontology : 12 A disease by infectious agent that results in infection, has material basis in Fungi, which pass the resistance barriers of the human or animal body.

MalaCards based summary : Fungal Infectious Disease, also known as mycoses, is related to primary systemic mycosis and sezary's disease. An important gene associated with Fungal Infectious Disease is CCR6 (C-C Motif Chemokine Receptor 6), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Ciclopirox and Amorolfine have been mentioned in the context of this disorder. Affiliated tissues include t cells, skin and testes, and related phenotypes are hematopoietic system and immune system

Sources

Related Diseases for Fungal Infectious Disease

About this section

Diseases related to Fungal Infectious Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1105)
# Related Disease Score Top Affiliating Genes
1 primary systemic mycosis 33.6 TNF TLR2 IL4 IL17A IL10 FLNC
2 sezary's disease 33.3 IL4 IL10 CD8A CD4 CCR6
3 superficial mycosis 32.8 CLEC7A CLEC6A CLEC4E
4 aspergillosis 32.8 TNF TLR2 IL4 IL10 CLEC7A CCR6
5 sporotrichosis 32.7 IL10 CLEC7A CD40LG CD4 CARD9
6 histoplasmosis 32.7 TNF IL17A CLEC7A CD8A CD40LG CD4
7 mucormycosis 32.6 RHNO1 FLNC CYP51A1 CLEC7A CD4 CCR6
8 pityriasis versicolor 32.5 CLEC7A CLEC6A CLEC4E
9 paracoccidioidomycosis 32.5 TNF TLR2 IL4 IL10 CD40LG
10 subcutaneous mycosis 32.5 IL17A FLNC CLEC7A CLEC6A CLEC4E CD4
11 chromoblastomycosis 32.5 IL4 CLEC7A CLEC6A CLEC4E CCR6 CARD9
12 tinea pedis 32.5 CYP51A1 CLEC7A CLEC6A CARD9
13 opportunistic mycosis 32.4 TNF TLR2 RHNO1 IL4 IL17RA IL17F
14 coccidioidomycosis 32.4 TNF IL17A CYP51A1 CLEC7A CLEC6A CD40LG
15 tinea corporis 32.4 CLEC6A CLEC4E CARD9
16 dermatophytosis 32.3 IL17A FLNC CYP51A1 CLEC7A CLEC6A CLEC4E
17 tinea cruris 32.2 CYP51A1 CLEC6A CARD9
18 blastomycosis 32.2 TNF IL17A CLEC7A CLEC6A CLEC4E CD40LG
19 parapsoriasis 31.9 CD8A CD4
20 dermatomycosis 31.8 CYP51A1 CLEC7A CD4
21 tinea capitis 31.8 FLNC CLEC6A CARD9
22 vulvovaginal candidiasis 31.8 TLR2 IL4 CLEC7A CLEC6A CCR6 CARD9
23 oral candidiasis 31.6 IL17RA IL17F IL17A CLEC7A CLEC6A CD8A
24 cryptococcal meningitis 31.6 CD8A CD4 CCR6
25 phaeohyphomycosis 31.6 CLEC7A CLEC6A CLEC4E CARD9
26 penicilliosis 31.6 CLEC7A CD4 CARD9
27 dermatitis 31.5 TNF IL4 IL17A IL10 CCR6
28 vitiligo-associated multiple autoimmune disease susceptibility 1 31.4 ICOSLG CD8A CD4 CCR6 AIRE
29 invasive aspergillosis 31.4 TLR2 IL10 FLNC CYP51A1 CLEC7A CLEC6A
30 acquired immunodeficiency syndrome 31.4 TNF IL10 CD40LG CD4 CCR6
31 african histoplasmosis 31.4 RHNO1 CD4
32 vaginitis 31.3 TNF TLR2 IL10 CD4 CCR6
33 lichen planus 31.3 TNF TLR2 IL4 IL17A IL10
34 t-cell adult acute lymphocytic leukemia 31.2 CD8A CD4 CCR6
35 purpura 31.2 TNF IL4 IL10 CD40LG
36 endophthalmitis 31.2 TNF TLR2 CD4 CARD9
37 pustulosis of palm and sole 31.2 TNF IL17A CCR6
38 seborrheic dermatitis 31.2 TNF CLEC4E CD4 CCR6
39 trichomoniasis 31.1 TNF CD40LG CD4
40 lymphopenia 31.1 IL4 IL10 ICOSLG CCR6
41 meningitis 31.1 TNF TLR2 IL4 IL17A IL10 CD40LG
42 american histoplasmosis 31.1 CD40LG CD4
43 pyoderma 31.1 TNF CD40LG CCR6
44 lymphoma, non-hodgkin, familial 31.0 TNF IL4 IL10 ICOSLG CD8A CD40LG
45 leishmaniasis 31.0 TNF TLR2 IL4 IL17A IL10
46 allergic contact dermatitis 31.0 TNF IL4 IL17F IL17A IL10 CD4
47 histiocytosis 31.0 TNF IL17A CCR6
48 pleural empyema 31.0 FLNC CD40LG CD4
49 peritonitis 31.0 TNF TLR2 IL4 IL17A IL10
50 alopecia areata 31.0 TNF IL4 IL17A IL10 ICOSLG AIRE

Graphical network of the top 20 diseases related to Fungal Infectious Disease:



Diseases related to Fungal Infectious Disease
Sources

Symptoms & Phenotypes for Fungal Infectious Disease

About this section

MGI Mouse Phenotypes related to Fungal Infectious Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.31 AIRE CARD9 CCR6 CD4 CD40LG CD8A
2 immune system MP:0005387 10.25 AIRE CARD9 CCR6 CD4 CD40LG CD8A
3 homeostasis/metabolism MP:0005376 10.24 AIRE CARD9 CCR6 CD4 CD40LG CLEC4E
4 digestive/alimentary MP:0005381 10.13 AIRE CD4 CLEC7A CYP51A1 IL10 IL17A
5 mortality/aging MP:0010768 10.03 AIRE CD4 CD40LG CD8A CLEC4E CLEC6A
6 integument MP:0010771 9.96 CD4 CD40LG CD8A FLNC IL10 IL17A
7 no phenotypic analysis MP:0003012 9.65 AIRE CD4 CLEC4E CLEC6A CYP51A1 IL10
8 respiratory system MP:0005388 9.32 AIRE CLEC7A FLNC IL10 IL17A IL17F
Sources

Drugs & Therapeutics for Fungal Infectious Disease

About this section

Drugs for Fungal Infectious Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 360)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ciclopirox Approved, Investigational Phase 4 29342-05-0 2749
2
Amorolfine Approved, Investigational Phase 4 78613-35-1
3
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
4
Anidulafungin Approved, Investigational Phase 4 166663-25-8 166548
5
Ibuprofen Approved Phase 4 15687-27-1 3672
6
Nystatin Approved, Vet_approved Phase 4 1400-61-9 11953884
7
Voriconazole Approved Phase 4 137234-62-9 71616
8
Busulfan Approved, Investigational Phase 4 55-98-1 2478
9
Dimethyl sulfoxide Approved, Vet_approved Phase 4 67-68-5 679
10
Metronidazole Approved Phase 4 443-48-1 4173
11
Gemcitabine Approved Phase 4 95058-81-4 60750
12
Oxaliplatin Approved, Investigational Phase 4 61825-94-3 43805 6857599 5310940 9887054
13
Etoposide Approved Phase 4 33419-42-0 36462
14
Ifosfamide Approved Phase 4 3778-73-2 3690
15
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
16
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
17
rituximab Approved Phase 4 174722-31-7 10201696
18
Cytarabine Approved, Experimental, Investigational Phase 4 147-94-4, 65-46-3 6253
19
Vincristine Approved, Investigational Phase 4 57-22-7, 2068-78-2 5978
20
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
21
Cisplatin Approved Phase 4 15663-27-1 2767 441203 84093
22
Epirubicin Approved Phase 4 56420-45-2 41867
23
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
24
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
25
Methoxsalen Approved Phase 4 298-81-7 4114
26
Micafungin Approved, Investigational Phase 4 235114-32-6 477468 3081921
27
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
28
Amphotericin B Approved, Investigational Phase 4 1397-89-3 5280965 14956
29 Keratolytic Agents Phase 4
30 Clorazepate Dipotassium Phase 4
31 Anti-Bacterial Agents Phase 4
32 Adjuvants, Immunologic Phase 4
33 Pharmaceutical Solutions Phase 4
34 Echinocandins Phase 4
35 Fluorides Phase 4
36
Hydroxyitraconazole Phase 4
37 Ionophores Phase 4
38 Immunologic Factors Phase 4
39 Cytochrome P-450 CYP3A Inhibitors Phase 4
40 Antibiotics, Antitubercular Phase 4
41 Immunosuppressive Agents Phase 4
42 Thymoglobulin Phase 4
43 Immunoglobulins Phase 4
44 Antibodies Phase 4
45 Antibodies, Monoclonal Phase 4
46 Etoposide phosphate Phase 4
47
Isophosphamide mustard Phase 4 0
48 Anti-Infective Agents Phase 4
49 Hormone Antagonists Phase 4
50 Cytochrome P-450 Enzyme Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 725)
# Name Status NCT ID Phase Drugs
1 Comparison of Methotrexate Versus Interferon-alfa 2b on Efficacy, Safety and Quality of Life in Patients With Primary Cutaneous T-cell Lymphomas Unknown status NCT02323659 Phase 4 Methotrexate;Interferon Alfa-2b
2 A Multicentre, Randomized, Controlled Study of the Efficacy, Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer Alone for the Treatment of Dermatophytic Onychomycosis (Toenail) Without Matrix Involvement Unknown status NCT01014637 Phase 4 Amorolfine (Antifungal);RV4104A, Ciclopiroxolamine, Cyclopirox (Keratolytic Agents/Antifungal)
3 Efficacy and Safety in Micafungin Sodium for Prophylaxis Against Invasive Fungal Disease During Neutropenia in Pediatric & Adolescent Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Unknown status NCT01135589 Phase 4 Micafungin
4 A Multicenter Open-Label Study to Evaluate the Safety and Efficacy of DAB389IL-2 in Cutaneous T-Cell Lymphoma (CTCL) Patients Following Protocol 93-04-10, Protocol 93-04-11, or Protocol 92-04-01 or Who Meet the Requirements for Protocol 93-04-11 Except Have Biopsy-Documented CTCL That Does Not Express CD25 Completed NCT00051012 Phase 4 ONTAK
5 A Multicenter Phase III Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy of Two Dose Levels of DAB389IL-2 (9 and 18 Mcg/kg/Day) in Cutaneous T-Cell Lymphoma (CTCL) Patients With Stage Ia-III Disease Who, Following Less Than or Equal to 3 Previous Therapies, Have Recurrent or Persistent Disease That Has Been Biopsy-Documented to Express CD25 Completed NCT00050999 Phase 4 ONTAK
6 UVADEX Sterile Solution in Conjunction With the UVAR XTS Photopheresis System as an Interventional Therapy for the Treatment Of CTCL (Mycosis Fungoides) in Patients With TMN Classification Stage 1A, 1B, 2A Completed NCT00221039 Phase 4 Methoxsalen+ECP
7 Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure Completed NCT01968395 Phase 4 Caspofungin 70 mg
8 An Open, Prospective, Uncontrolled, Multi-Center Study To Evaluate The Efficacy And Safety Of Voriconazole In Chinese Subjects With Proven Or Probable Serious Invasive Fungal Infections Completed NCT00288197 Phase 4 voriconazole
9 Population Pharmacokinetic Analysis of Caspofungin in Overweight and Obese Volunteers Completed NCT01062165 Phase 4 Caspofungin
10 Prospective, Open-Label, Non-Comparative, Multicenter Study for the Secondary Prophylaxis of Invasive Fungal Infections (IFI) With Voriconazole in Patients With Allogeneic Stem Cell Transplants (SCT). Completed NCT00143312 Phase 4 voriconazole
11 Assessment Of Voriconazole Penetration Into The Brain By Fluorine-Magnetic Resonance Spectroscopy Completed NCT00300677 Phase 4 voriconazole
12 A Randomized, Parallel, Single-Dose Study to Evaluate the Pharmacokinetics of Two Different Formulation of Voriconazole 200mg Tablets in Healthy Adult Subjects Completed NCT02912156 Phase 4 Vaway FC Tablets 200mg (Voriconazole);VFEND FC Tablets 200mg (Voriconazole)
13 Anidulafungin Versus Fluconazole for the Prevention of Invasive Fungal Infections in High-risk Liver Transplant Recipients: a Randomized, Double-blind Trial Completed NCT00841971 Phase 4 Anidulafungin;Fluconazole
14 A Phase 4 Study of the Pharmacokinetics of Oral Posaconazole (SCH 56592) Among Patients With Compromised Gastrointestinal Function and at High Risk for Invasive Fungal Infection Completed NCT00686543 Phase 4 Posaconazole
15 ANTIVORIFUNGOL:Strategy of Antifungal Use in Oncohematological Neutropenic Patients. Use of Voriconazole as Early Treatment. Completed NCT00386802 Phase 4 Antifungal drug. VORICONAZOL. (VFEND®)
16 Phase IV Randomized Study of Two Dose Levels of Targretin® Capsules in Subjects With Refractory Cutaneous T-Cell Lymphoma Completed NCT01007448 Phase 4 Bexarotene
17 Multicenter, Randomized, Open-label Clinical Trial to Compare Anidulafungin Versus Amphotericin B Safety in High Risk Hepatic Transplant Recipients Completed NCT01303549 Phase 4 Anidulafungin;Liposomal amphotericin B
18 Effect of Granulocyte-macrophage Stimulating Factor on Prevention and Treatment of Invasive Fungal Diseases in the Recipients of Allogeneic Stem Cell Transplantation: A Prospective Multicenter Randomized Phase 4 Trial Completed NCT01232504 Phase 4 rhGM-CSF group;rhG-CSF+rhGM-CSF group;rhG-CSF group
19 Pharmacokinetic Analysis of Micafungin in Overweight, Obese, and Extremely Obese Volunteers Completed NCT01090141 Phase 4 Micafungin;Micafungin
20 An Open Label, Non-comparative, Multicenter Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infection Completed NCT00647907 Phase 4 Voriconazole
21 Safety of Fluconazole Treatment of Premature and Full-term Newborn Infants - A Study on Interactions by Nonsteroidal Anti Inflammatory Drugs (NSAIDs) With Fluconazole in Respect of Pharmacodynamic Endpoints With Urinary Excretion of Vasoactive Endobiotics Completed NCT02079298 Phase 4 Treatment with fluconazole.;2. Treatment with both fluconazole and Ibuprofen.;3. Treatment with ibuprofen.
22 Oral Nystatin Prophylaxis to Prevent Systemic Fungal Infection in Very Low Birth Weight Preterm Infants: a Randomized Controlled Trial Completed NCT03390374 Phase 4 Nystatin Oral
23 A Randomized Open-Label Trial of Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
24 Invasive Fungal Infection in Liver Transplant Recipients: A Randomized Double-Blind Trial Comparing AmBisome and Fluconazole in the High Risk Group and an Observational Cohort Study in the Low Risk Completed NCT00001107 Phase 4 Fluconazole;AmBisome
25 Clinical Efficacy and Safety of Itraconazole Injection/Oral Solution Sequential Therapy for Treatment of Invasive Pulmonary Fungal Infections Completed NCT01823289 Phase 4 Itraconazole
26 Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections Completed NCT02805946 Phase 4 posaconazole
27 Population Pharmacokinetic Analysis of Anidulafungin in Normal, Overweight and Obese Volunteers Completed NCT01307930 Phase 4 Anidulafungin
28 Efficacy of Itraconazole as Secondary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation or Chemotherapy With Prior Invasive Fungal Infection Completed NCT01198236 Phase 4 Itraconazole
29 A Prospective, Randomized Trial Comparing the Efficacy and Safety of Voriconazole Administered With Therapeutic Drug Monitoring vs. Standard Dosing Completed NCT01416025 Phase 4 Prospective TDM Arm
30 Clinical Study to Evaluate the Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Pediatric Solid Tumors Completed NCT00336531 Phase 4 itraconazole
31 Assessment of Target Site Pharmacokinetics of Voriconazole in Healthy Volunteers During Sequence Therapy Completed NCT01539330 Phase 4 Voriconazole
32 Single Dose Population Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients Completed NCT02968134 Phase 4 Posaconazole
33 The Use of Antifungal Lock Therapy in Intestinal Failure and Other Patients Completed NCT00936910 Phase 4 amphotericin B liposomal (Ambisome)
34 Itraconazole in the Management of Superficial Fungal Infections in India. A Pilot Study Recruiting NCT03923010 Phase 4 Itraconazole
35 Prediction of Itraconazole Oral Absorption From In Vitro Dissolution Recruiting NCT04035187 Phase 4 fast itraconazole tablet;medium itraconazole tablet;slow itraconazole tablet;oral itraconazole solution
36 Fluconazole Pharmacokinetics, Including Bioavailability, in Obese Subjects After an Intravenous and Oral Administration (FOLIA) Recruiting NCT04122560 Phase 4 Fluconazole 200mg tab;Fluconazole 2 MG/ML
37 Randomized and Multicenter Clinical Trial to Evaluate the Effectiveness and Efficiency of a Voriconazole Preemptive Genotyping Strategy in Patients With Risk of Aspergillosis Recruiting NCT04238884 Phase 4 Voriconazole preemptive genotyping strategy;Voriconazole clinical practice
38 Pharmacokinetics Study of Posaconazole in Haematology Patients Receiving Standard of Care Treatment With Oral Posaconazole Prophylaxis for Invasive Fungal Infection Recruiting NCT03717623 Phase 4 Posaconazole pharmacokinetics
39 Comparison of Effectiveness of Topical Amphotericin B in 30% Dimethylsulphoxide and 30% Dimethylsulphoxide in Treating of Non-dermatophytes Onychomycosis: Randomized Double Blind Controlled Trial Pilot Study Recruiting NCT03814343 Phase 4 amphotericin B in 30% DMSO;30% DMSO
40 Hematology , Shanghai Jiaotong University Affiliated Shanghai First People's Hospital, Shanghai, China Recruiting NCT02938741 Phase 4 Anti－human Thymoglobulin;Placebo
41 Controlled, Multicenter, Randomized Parallel Group Pilot Study With 2 Treatment Arms in Non-pregnant Women With Acute Symptomatic Bacterial Vaginosis (BV) Recruiting NCT02042287 Phase 4 Metronidazole
42 A Randomized Controlled Trial of the Effect of Cytochrome P450 2C19 Genotype-Specific Dosing Plus TDM vs. TDM Alone on Reaching Therapeutic Voriconazole Blood Levels Recruiting NCT03731169 Phase 4 Standard of Care
43 Study of PD-1 Monoclonal Antibody in Combination With Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Not yet recruiting NCT04134247 Phase 4 PD-1 combined with chemotherapy;chemotherapy
44 Prospective, Randomized Multicentic to Compare PUVA+IFN Alpha 2a vs PUVA Alone in Mycosis Fungoides Stages Ia, Ib or IIa. Terminated NCT00630903 Phase 4 PUVA (8MOP + UVA) + IFN;PUVA (8-MOP + UVA)
45 A Multi-center, Open-label, Non-comparative Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia (CFDA Commitment) Terminated NCT01982071 Phase 4 Micafungin
46 A Multi-center, Open-label, Non-comparative Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Aspergillosis (CFDA Commitment) Terminated NCT02646774 Phase 4 Micafungin
47 A Multi-center, Open-label, Non-comparative Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp Terminated NCT02646800 Phase 4 Micafungin
48 A Pharmacokinetic Analysis of Posaconazole in the Plasma and Alveolar Compartment of Lung Transplant Recipients Terminated NCT01667107 Phase 4 Posaconazole;Calogen®
49 ProphyALL - Pilot Study on Safety of Four Weekly Administrations of 7 mg/kg of Liposomal Amphotericin B (AmBisome®) in Antifungal Primary Prophylaxis Treatment of Elderly Patients With Acute Lymphoblastic Leukemia Undergoing Induction Chemotherapy Within the GMALL-Elderly Protocol Terminated NCT00386997 Phase 4 liposomal amphotericin B (AmBisome®)
50 Open Label, Limited Access Protocol of Posaconazole in Invasive Fungal Infections Study PO2095 Terminated NCT00177749 Phase 4 Posaconazole

Search NIH Clinical Center for Fungal Infectious Disease

Cochrane evidence based reviews: mycoses

Sources

Genetic Tests for Fungal Infectious Disease

About this section
Sources

Anatomical Context for Fungal Infectious Disease

About this section

MalaCards organs/tissues related to Fungal Infectious Disease:

40
T Cells, Skin, Testes, Bone, Liver, Bone Marrow, Lung
Sources

Publications for Fungal Infectious Disease

About this section

Articles related to Fungal Infectious Disease:

(show top 50) (show all 4677)
# Title Authors PMID Year
1
Cell wall polysaccharides from pathogenic fungi for diagnosis of fungal infectious disease. 61
32401381 2020
2
Treatment of invasive fungal diseases in cancer patients-Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). 61
32236989 2020
3
Unusual dermatomycoses caused by Nannizzia nana: the geophilic origin of human infections. 61
32232786 2020
4
Fungal prostatitis due to endemic mycoses and Cryptococcus: A multicenter case series. 61
32572997 2020
5
Medication association and immunomodulation: An approach in fungal diseases and in particular in the treatment of paracoccidioidomycosis. 61
32135141 2020
6
Vultures from different trophic guilds show distinct oral pathogenic yeast signatures and co-occurrence networks. 61
32224410 2020
7
In Vitro Evaluation of Radiolabeled Amphotericin B for Molecular Imaging of Mold Infections. 61
32393491 2020
8
Epidemiology and risk factors for invasive fungal disease in liver transplant recipients in a tertiary transplant center. 61
32510755 2020
9
AIDS-Related Mycoses: Updated Progress and Future Priorities. 61
32396822 2020
10
IL-22 Promotes IFN-γ-Mediated Immunity against Histoplasma capsulatum Infection. 61
32517114 2020
11
Species distribution of the main aetiologic agents causing skin dermatophytosis in Colombian patients: A 23-year experience at a Mycological Reference Center. 61
32163641 2020
12
Antifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond. 61
32441527 2020
13
Ebselen nanoemulgel for the treatment of topical fungal infection. 61
32259677 2020
14
Superficial mycoses in Belgium: Burden, costs and antifungal drugs consumption. 61
32048335 2020
15
A Retrospective Analysis of Invasive Fungal Diseases (IFD) of the Central Nervous System in Children With Lymphoid Malignancies. 61
31815886 2020
16
Canine systemic mycosis associated with Chaetomium globosum in a dog. 61
31971255 2020
17
Epidemiology of visceral mycoses in patients with acute leukemia and myelodysplastic syndrome: Analyzing the national autopsy database in Japan. 61
32400871 2020
18
Antifungal Activity of Gentamicin B1 Against Systemic Plant Mycoses. 61
32455775 2020
19
Evaluation of a PCR-electrospray ionization mass spectrometry platform for detection and identification of fungal pathogens directly from prospectively collected bronchoalveolar lavage specimens. 61
32107092 2020
20
Rosemary (Rosmarinus officinalis L., syn Salvia rosmarinus Spenn.) and Its Topical Applications: A Review. 61
32455585 2020
21
Clinical mycology today: A synopsis of the mycoses study group education and research consortium (MSGERC) second biennial meeting, September 27-30, 2018, Big Sky, Montana, a proposed global research agenda. 61
32407483 2020
22
Screening for invasive fungal disease using non-culture-based assays among inpatients with advanced HIV disease at a large academic hospital in South Africa. 61
32125004 2020
23
Development of a novel β-1,6-glucan-specific detection system using functionally-modified recombinant endo-β-1,6-glucanase. 61
32132174 2020
24
Photodynamic therapy treatment of superficial fungal infections: a systematic review. 61
32339671 2020
25
A retrospective cohort of invasive fusariosis in the era of antimould prophylaxis. 61
31231772 2020
26
Deep fungal infections diagnosed by histology in Uganda: a 70-year retrospective study. 61
32242631 2020
27
US database study: burden and healthcare resource utilization in adults with systemic endemic mycoses and aspergillosis. 61
32316748 2020
28
Evaluation of Commercially Available Real-Time Polymerase Chain Reaction Assays for the Diagnosis of Invasive Aspergillosis in Patients with Haematological Malignancies. 61
31950340 2020
29
Fungal lung disease. 61
32527608 2020
30
Genes coding for LysM domains in the dermatophyte Trichophyton rubrum: A transcription analysis. 61
31226713 2020
31
Sporotrichosis: A Clinicopathologic Study of 89 Consecutive Cases, Literature Review, and New Insights About Their Differential Diagnosis. 61
32149828 2020
32
The interaction between Sporothrix schenckii sensu stricto and Sporothrix brasiliensis with Acanthamoeba castellanii. 61
31820499 2020
33
Cerebral phaeohyphomycosis caused by Alternaria spp.: A case report. 61
31879586 2020
34
Bridging the knowledge gap on mycoses in Africa: Setting up a Pan-African Mycology Working Group. 61
31829454 2020
35
Evaluation of galactomannan and beta-d-glucan assays for the diagnosis of invasive aspergillosis in clinically suspected cases. 61
32207422 2020
36
Frequency of Invasive Fungal Disease in Adults: Experience of a Specialized Laboratory in Medellín, Colombia (2009-2015). 61
32244949 2020
37
Evaluation of the expanding spectrum of sertraline against uncommon fungal pathogens. 61
31678053 2020
38
A national survey on fungal infection diagnostic capacity in the clinical mycology laboratories of tertiary care hospitals in China. 61
32334978 2020
39
Chilean aquaculture and the new challenges: Pathogens, immune response, vaccination and fish diversification. 61
31899356 2020
40
Re-drawing the Maps for Endemic Mycoses. 61
32040709 2020
41
More than flipping the lid: Cdc50 contributes to echinocandin resistance by regulating calcium homeostasis in Cryptococcus neoformans. 61
32274390 2020
42
New Insights on Pulmonary Paracoccidioidomycosis. 61
32000284 2020
43
An Overview on Conventional and Non-Conventional Therapeutic Approaches for the Treatment of Candidiasis and Underlying Resistance Mechanisms in Clinical Strains. 61
32050673 2020
44
Hospitalisations for mycoses as an indicator of socio-environmental vulnerability in the Brazilian Amazon-Savanna transition region. 61
31758620 2020
45
Non-Aspergillus Hyaline Molds: Emerging Causes of Sino-Pulmonary Fungal Infections and Other Invasive Mycoses. 61
32000288 2020
46
Detection of Rhizopus-specific antigen in human and murine serum and bronchoalveolar lavage. 61
32060526 2020
47
Risk Factors Associated With Invasive Fungal Infections in Kidney Transplant Patients. 61
31836132 2020
48
Analysis of cases managed by dermatological service in the Chinese peacekeeping level 1+ medical treatment facility in Lebanon, 2018-2019. 61
32111673 2020
49
Impact of IVIG therapy on serologic testing for infectious diseases. 61
31787407 2020
50
A case of invasive pulmonary aspergillosis diagnosed by transbronchial lung biopsy during treatment for diabetic ketoacidosis in a type 1 diabetic patient. 61
31542205 2020
Sources

Variations for Fungal Infectious Disease

About this section
Sources

Expression for Fungal Infectious Disease

About this section
Search GEO for disease gene expression data for Fungal Infectious Disease.
Sources

Pathways for Fungal Infectious Disease

About this section

Pathways related to Fungal Infectious Disease according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 13.82 TNF TLR2 IL4 IL17RA IL17F IL17A
2
ERK Signaling 63
Show member pathways
 13.78 TNF IL4 IL17RA IL17A IL10 FLNC
3
PEDF Induced Signaling 63
Show member pathways
 13.64 TNF IL4 IL17RA IL17F IL17A IL10
4
Akt Signaling 63
Show member pathways
 13.39 TNF TLR2 IL4 IL17RA IL17A IL10
5
Cytokine Signaling in Immune system 65
Show member pathways
 13.33 TNF IL4 IL17RA IL17F IL17A IL10
6
PAK Pathway 63
Show member pathways
 13.3 TNF IL4 IL17RA IL17A IL10 FLNC
7
Allograft rejection 1 36
Show member pathways
 12.75 TNF IL4 IL17A IL10 ICOSLG CD8A
8
Immune response NFAT in immune response 22
Show member pathways
 12.63 TNF IL4 IL10 ICOSLG CD40LG CD4
9
Th17 cell differentiation 36
Show member pathways
 12.58 TNF TLR2 IL4 IL17F IL17A IL10
10
Immune response IL-23 signaling pathway 22
Show member pathways
 12.56 TNF IL17F IL17A IL10 CD4
11
T cell receptor signaling pathway 36
Show member pathways
 12.4 TNF TLR2 IL4 IL17A IL10 CD8A
12
CLEC7A (Dectin-1) signaling 65
Show member pathways
 12.37 CLEC7A CLEC6A CLEC4E CARD9
13
IL-17 Family Signaling Pathways 64
Show member pathways
 12.34 TNF TLR2 IL4 IL17RA IL17F IL17A
14
Toxoplasmosis 36
Show member pathways
 12.26 TNF TLR2 IL4 IL10 CD40LG
15
Tuberculosis 36
12.21 TNF TLR2 IL10 CLEC7A CLEC4E CARD9
16
C-type lectin receptor signaling pathway 36
Show member pathways
 12.17 TNF IL10 CLEC7A CLEC6A CLEC4E CARD9
17
Cell adhesion molecules (CAMs) 36
12.09 ICOSLG CD8A CD40LG CD4
18
NF-kappaB Signaling 4
12.07 TNF TLR2 IL4 IL17A IL10 CD8A
19
Hematopoietic Stem Cells and Lineage-specific Markers 64
12.02 TNF IL4 IL10 CD8A CD4
20
Interleukin-4 and 13 signaling 65
12 TNF IL4 IL17F IL17A IL10
21
Hematopoietic cell lineage 36
11.9 TNF IL4 CD8A CD4
22
IL27-mediated signaling events 1
Show member pathways
 11.87 TNF TLR2 IL17F IL17A IL10 CD4
23
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.71 TNF IL4 CD40LG
24
Dendritic Cells Developmental Lineage Pathway 64
11.7 TNF IL17RA IL10 CD8A CD4
25
IL4-mediated signaling events 1
11.62 IL4 IL10 CD40LG
26
Th17 Differentiation 64
Show member pathways
 11.59 TLR2 IL4 IL17RA IL17F IL17A CD4
27
Malaria 36
11.57 TNF TLR2 IL10 CD40LG
28
Interleukin-10 signaling 65
11.5 TNF IL4 IL10
29
Th2 Differentiation 64
11.47 IL4 IL10 CD4
30
Primary immunodeficiency 36
11.42 CD8A CD40LG CD4 AIRE
31
Development and heterogeneity of the ILC family 1
11.29 TNF IL4 IL17A
32
Cytokines and Inflammatory Response 1
11.27 TNF IL4 IL10 CD4
33
Innate Lymphoid Cells Differentiation 64
11.07 TNF IL4 IL17A IL10 CD8A CD4
Sources

GO Terms for Fungal Infectious Disease

About this section

Cellular components related to Fungal Infectious Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.8 TNF TLR2 IL17RA ICOSLG FLNC CYP51A1
2 cell surface GO:0009986 9.63 TNF TLR2 CLEC7A CD40LG CD4 CCR6
3 external side of plasma membrane GO:0009897 9.17 TNF IL17A ICOSLG CD8A CD40LG CD4

Biological processes related to Fungal Infectious Disease according to GeneCards Suite gene sharing:

(show all 38)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.19 TNF TLR2 IL4 IL17F IL17A IL10
2 immune system process GO:0002376 10.01 TLR2 ICOSLG CLEC7A CLEC6A CLEC4E CD8A
3 regulation of immune response GO:0050776 9.96 IL4 ICOSLG CD8A CD40LG
4 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.93 TNF CLEC6A CD4 CARD9
5 inflammatory response GO:0006954 9.93 TNF TLR2 IL17F IL17A CLEC7A CD40LG
6 cytokine-mediated signaling pathway GO:0019221 9.91 TNF IL4 IL17F IL17A IL10 CD4
7 B cell differentiation GO:0030183 9.85 IL4 IL10 CD40LG
8 positive regulation of T cell proliferation GO:0042102 9.81 IL4 CD40LG CD4
9 humoral immune response GO:0006959 9.81 TNF CCR6 AIRE
10 positive regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043280 9.8 TNF CLEC7A CARD9
11 positive regulation of interleukin-6 production GO:0032755 9.79 TNF TLR2 CARD9
12 defense response to fungus GO:0050832 9.7 IL17RA IL17A CLEC6A
13 microglial cell activation GO:0001774 9.69 TNF TLR2 IL4
14 negative regulation of tumor necrosis factor biosynthetic process GO:0042536 9.68 IL4 IL10
15 response to molecule of bacterial origin GO:0002237 9.67 TLR2 IL10
16 negative regulation of amyloid-beta clearance GO:1900222 9.67 TNF CYP51A1
17 positive regulation of MHC class II biosynthetic process GO:0045348 9.66 IL4 IL10
18 positive regulation of interleukin-1 beta biosynthetic process GO:0050725 9.65 TNF IL17A
19 endothelial cell apoptotic process GO:0072577 9.65 TNF IL10
20 positive regulation of interleukin-10 production GO:0032733 9.65 TLR2 IL4 CD40LG
21 positive regulation of interleukin-12 biosynthetic process GO:0045084 9.64 IL17A CLEC7A
22 positive regulation of interleukin-6 secretion GO:2000778 9.62 TNF TLR2 IL17F IL17A
23 positive regulation of mononuclear cell migration GO:0071677 9.61 TNF IL4
24 type 2 immune response GO:0042092 9.61 IL4 IL10
25 negative regulation of cytokine production involved in immune response GO:0002719 9.6 TNF IL10
26 regulation of immunoglobulin secretion GO:0051023 9.59 TNF CD40LG
27 positive regulation of interleukin-23 production GO:0032747 9.58 IL17RA IL17A
28 negative regulation of cytokine secretion involved in immune response GO:0002740 9.58 TNF IL10
29 fibroblast activation GO:0072537 9.57 IL17RA IL17A
30 regulation of interleukin-6 biosynthetic process GO:0045408 9.56 IL17F CARD9
31 positive regulation of cytokine secretion GO:0050715 9.56 TNF IL10 CLEC6A CLEC4E
32 regulation of isotype switching GO:0045191 9.55 IL4 IL10
33 T cell activation GO:0042110 9.55 IL4 ICOSLG CLEC7A CD8A CD4
34 receptor biosynthetic process GO:0032800 9.54 TNF IL10
35 interleukin-17-mediated signaling pathway GO:0097400 9.54 IL17RA IL17F IL17A
36 regulation of interleukin-2 biosynthetic process GO:0045076 9.49 IL17F CARD9
37 immune response GO:0006955 9.36 TNF TLR2 IL4 IL17A IL10 CLEC4E
38 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.35 TNF IL17RA IL17F IL17A CLEC7A

Molecular functions related to Fungal Infectious Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor activity GO:0038023 9.46 TLR2 CLEC4E CD4 CCR6
2 pattern recognition receptor activity GO:0038187 9.13 TLR2 CLEC7A CLEC4E
3 cytokine activity GO:0005125 9.1 TNF IL4 IL17F IL17A IL10 CD40LG
Sources

Sources for Fungal Infectious Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....